Explore how biomarkers can predict BCG failure in high-risk bladder cancer, aiding in personalized treatment strategies.
Learn how intelligent medical records enhance patient care, streamline workflows, and improve healthcare outcomes through ...
The FDA has approved atezolizumab combined with chemotherapy for treating stage III dMMR colon cancer, enhancing post-surgery treatment options.
In September, the U.S. Food and Drug Administration (FDA) granted fast track designation to investigational therapies and diagnostic products across a range of cancer types, including lung and ...
A study suggests that a reduced dose of enfortumab vedotin may lower toxicity in older patients with urothelial carcinoma, ...
Explore a comparative study on ESR1 mutation testing using dPCR and NGS. Understand the strengths and applications of each ...
On Oct. 2, the U.S. Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who ...
At WCLC 2026, three thoracic oncologists discuss first-line regimen selection, subcutaneous dosing, dermatologic prophylaxis, and dose modifications in EGFR-mutant NSCLC. Subcutaneous amivantamab has ...
Recent headlines on leadership appointments, executive transitions, and notable recognitions spotlight the leaders helping to shape oncology research, patient care, and cancer organizations. MD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results